Supreme Court Showdown: Battle Over Mail-Order Mifepristone Access

Danco Laboratories seeks a Supreme Court stay against an appeals court ruling limiting mail-order mifepristone access. The conservative panel ruling, following a Louisiana Republican-led case, challenges FDA regulations allowing the mail service due to potential drug risks, igniting medico-legal confusion. This follows ongoing disputes over the drug's approval since 2000.

Danco Laboratories has appealed to the U.S. Supreme Court to halt an appellate court's decision blocking the mail distribution of mifepristone, an abortion drug. This recent ruling, issued by a conservative three-judge panel, restricts access nationwide, with Danco arguing it creates turmoil over medical decisions.

The case was initiated by Louisiana, which criticized the FDA's 2023 regulation that permitted mailing the drug, citing ignored risks such as sepsis and hemorrhaging. Although the Supreme Court will soon review the case, the current decision is a significant step in limited access amid numerous legal battles since the drug's 2000 approval.

Both Danco and GenBioPro are defending the FDA's regulation against Louisiana's lawsuit. As the legality of mail-order mifepristone is debated, states like Missouri, Kansas, and Idaho have joined the legal battle. Concerns about mifepristone's safety remain subject to further scrutiny, with a comprehensive federal review delayed until after upcoming elections.